[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-456304-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-456304-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","sponge-application-of-mitomycin-c-vs-sub-tenon-injection-in-trabeculectomy-a-randomized-controlled-trial","Sponge Application of Mitomycin C vs Sub-Tenon Injection in Trabeculectomy - A Randomized Controlled Trial","","Evaluating glaucoma surgery optimization, this prospective randomized controlled trial compared trabeculectomy (TE) augmented with mitomycin C delivered by sponge application versus sub-Tenon injection (STI-MMC). Fifty primary or secondary glaucoma patients were assigned to sponge-applied MMC (n=25) or STI-MMC (n=25) and followed for 12 months. Primary efficacy focused on intraocular pressure (IOP) reduction; secondary outcomes assessed bleb morphology using IBAGS, bleb integrity via Seidel testing, and postoperative medication needs. Both groups achieved significant IOP decreases with no intergroup differences (p>0.05). Distinct bleb morphology emerged (p\u003C0.001), while vascularity and integrity showed no significant differences. Medication requirements were comparable (p=0.732).",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sponge-application-of-mitomycin-c-vs-sub-tenon-injection-in-trabeculectomy-a-randomized-controlled-trial/456304/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sponge-application-of-mitomycin-c-vs-sub-tenon-injection-in-trabeculectomy-a-randomized-controlled-trial/456304.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study aim regarding mitomycin C delivery in trabeculectomy?","Question",{"text":63,"@type":64},"To compare efficacy and safety of TE using MMC sponge application versus STI-MMC, focusing on outcomes related to IOP control and bleb characteristics.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the primary and secondary outcome measures?",{"text":68,"@type":64},"Primary outcomes assessed intraocular pressure reduction. Secondary outcomes included bleb morphology via IBAGS, bleb integrity by Seidel testing, bleb vascularity, and the need for postoperative glaucoma medications.",{"name":70,"@type":61,"acceptedAnswer":71},"Did sponge-applied MMC and STI-MMC differ in IOP reduction?",{"text":72,"@type":64},"No. Both groups achieved significant IOP reductions at all postoperative intervals with no intergroup differences (p>0.05).",{"name":74,"@type":61,"acceptedAnswer":75},"How did the two treatments differ in bleb morphology?",{"text":76,"@type":64},"Bleb morphology differed significantly: group A showed higher localized blebs, while group B produced flatter and more diffuse blebs (p\u003C0.001).","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},456304,1790791670,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},7,40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},8,"Research & Report",30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","original rESEarCH  \nSponge Application of Mitomycin C vs Sub-Tenon Injection in Trabeculectomy: A Randomized Controlled Trial  \nSayed Mostafa Elsayed Abdelhafeez1, Hazem Elbadry Mohammed Mohammed2, Ehab Tharwat3,  \nMohamed Mohamed-Aly Ibrahim4, Ahmed Mohamed Raafat Tawfik5, Ramadan Mohamed Abdelrahman Elgohary6, Mohammed Saad Ibrahim Alabshihy7, Ahmed Mohammed Sakr8, Anas M Ebrahim9, Ahmed Rabie Mohammed10, Nehad Mohammed Yusef11, Emad A Saliem12, Sherif Salah Eid Elsayed13, Ehab Mohamed Elsayed Saad14  \nReceived on: 10 June 2025; Accepted on: 29 October 2025; Published on: 15 December 2025  \nAbstrAct  \nAims and background: Glaucoma represents a major driver of irreversible blindness globally, with intraocular pressure (IOP) reduction serving as the primary therapeutic objective. Trabeculectomy (TE), often augmented with mitomycin C (MMC), is considered the gold standard surgical treatment; however, its success is frequently compromised by postoperative fibrosis. Various MMC delivery techniques—such as sponge application and sub-Tenon injection (STI)—differ in their drug distribution profilesand may consequently affect surgical outcomes. Accordingly, we aimed to evaluate and compare the efficacy and safety of TE performed with sponge-applied MMC against STI-MMC.  \nMaterials and methods: This prospective, randomized, controlled clinical trial enrolled 50 patients having primary or secondary glaucoma who were randomly allocated to undergo TE with either MMC sponge application (group A, n = 25) or STI-MMC (group B, n = 25) and followed for 12 months. The primary outcome measures included IOP reduction, while secondary outcomes assessed bleb morphology using the Indiana Bleb Appearance Grading Scale (IBAGS), bleb integrity via Seidel testing, and the requirement for postoperative glaucoma medications. Results: Both groups achieved significant IOP reductions without intergroup differences at all postoperative intervals (p > 0.05). Bleb morphology differed significantly, with higher localized blebs in group A and flatter and more diffuse blebs in group B (p \u003C 0.001). There were no significant differences in bleb vascularity or integrity. Postoperative medication needs were comparable (p = 0.732) .  \nConclusion: Both STI-MMCand sponge-applied MMC are equally effective for IOP control, though STI may produce more diffuse blebs, potentially reducing long-term complications. Further long-term studies are warranted.  \nClinical significance: This study demonstrates STI-MMC noninferiority compared to sponge-applied MMC in achieving sustained IOP reduction after TE while highlighting distinct bleb morphologies with potential safety implications. These findings advocate for individualized MMC selection based on patient-specific risk factors, balancing technical simplicity with potential long-term safety.  \nClinical trial [registration:](registration: Retrospectively registered at ClinicalTrials.gov)[ Retrospectively registered at ClinicalTrials.gov](registration: Retrospectively registered at ClinicalTrials.gov) (Identifier: NCT06925412).  \nKeywords: Glaucoma, Mitomycin C, Sponge application, Sub-Tenon, Trabeculectomy.  \nJournal of Current Glaucoma Practice (2025): 10.5005/jp-journals-10078-1500  \nIntroductIon  \nGlaucoma, commonly linked to increased intraocular pressure (IOP), is a primary cause of permanent blindness globally, marked by progressive optic neuropathy and impairment of the visual field.1 The principal intervention is lowering IOP to avert disease advancement and protect visual acuity. While laser and medicinal therapies are commonly utilized, surgical intervention is necessitated when pharmacological treatments inadequately manage IOP.2 Initially introduced in 1968, trabeculectomy (TE) is the preeminent surgical method for managing glaucoma. This method creates a filtration bleb from the anterior chamber to the subconjunctival space, hence enhancing aqueous humor drainage. The TE outcomes are often constrained by postoperativ","cbCaikD4Yt7UPqTw","https://ap.wps.com/l/cbCaikD4Yt7UPqTw","pdf",1789587,"English","# Abstract\n## Aims and background\n## Materials and methods\n## Results\n## Conclusion\n## Clinical significance\n# Introduction\n## Glaucoma and trabeculectomy background\n## Role of antiproliferative agents\n## Wound-healing and fibrosis in TE","[{\"question\":\"What was the study aim regarding mitomycin C delivery in trabeculectomy?\",\"answer\":\"To compare efficacy and safety of TE using MMC sponge application versus STI-MMC, focusing on outcomes related to IOP control and bleb characteristics.\"},{\"question\":\"What were the primary and secondary outcome measures?\",\"answer\":\"Primary outcomes assessed intraocular pressure reduction. Secondary outcomes included bleb morphology via IBAGS, bleb integrity by Seidel testing, bleb vascularity, and the need for postoperative glaucoma medications.\"},{\"question\":\"Did sponge-applied MMC and STI-MMC differ in IOP reduction?\",\"answer\":\"No. Both groups achieved significant IOP reductions at all postoperative intervals with no intergroup differences (p\\u003e0.05).\"},{\"question\":\"How did the two treatments differ in bleb morphology?\",\"answer\":\"Bleb morphology differed significantly: group A showed higher localized blebs, while group B produced flatter and more diffuse blebs (p\\u003c0.001).\"}]","Sponge Application of Mitomycin C vs Sub-Tenon Injection in Trabeculectomy - A Randomized Controlled Trial | PDF",1790745517,23]